Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals was a clinical-stage oncology company whose TERN news centered on TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia. Company updates covered clinical and regulatory disclosures for TERN-701, licensing arrangements tied to the program, operating and financial results, equity compensation actions, and shareholder or capital-structure matters.
In May 2026, Merck completed its acquisition of Terns, and Terns became a wholly owned subsidiary of Merck. The company’s common stock was removed from Nasdaq trading, making TERN a historical public-company ticker tied to the oncology program and the completed corporate-status change.
Terns Pharmaceuticals, a biopharmaceutical company, announces positive data from a Phase 1 study of TERN-701, a potential BCR-ABL inhibitor for CML treatment, showing no food effect on dosing. The ongoing study in healthy volunteers displayed promising results, supporting once-daily dosing with or without food. The company aims to differentiate TERN-701 from the current standard, asciminib, by offering more convenient dosing options. Phase 1 CARDINAL trial is ongoing, with interim data expected in late 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.